Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Forest Expects Memantine NDA In June; Readies For Benicar Sampling

  • News

Executive Summary

Forest expects to submit an NDA for the Alzheimer's drug memantine in June, the company told analysts at the Deutsche Bank healthcare conference in Baltimore May 7

You may also be interested in...



Forest Adding 600 Sales Reps For Memantine, Lercanidipine Launches

Forest is planning to add a 600-rep sales force to support the upcoming launches of the Alzheimer's agent memantineand the anti-hypertensive lercanidipine, President Kenneth Goodman told analysts Oct. 15

Forest Adding 600 Sales Reps For Memantine, Lercanidipine Launches

Forest is planning to add a 600-rep sales force to support the upcoming launches of the Alzheimer's agent memantineand the anti-hypertensive lercanidipine, President Kenneth Goodman told analysts Oct. 15

Sankyo/Forest Benicar Launch Set For May; Seventh Angiotensin II Inhibitor

Sankyo and Forest will launch the angiotensin II inhibitorBenicar (olmesartan) with a 1,200-person sales force

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS039857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By